Lifeboat Foundation

Researchers from an international collaboration have succeeded in creating a “protein cage”—a nanoscale structure that could be used to deliver drugs to specific places of the body, and which can be readily assembled and disassembled, but also withstands boiling and other extreme conditions. They did this by exploring geometries not found in nature reminiscent of “paradoxical geometries” found in Islamic art.

Role-playing gamers—at least those who played before the digital age—are aware that there are restrictions governing the shape of dice; try to make a six-sided die by replacing the square faces with triangles, and you will be left with something horribly distorted and certainly not fair. This is because there are strict geometrical rules governing the assembly of these so-called isohedra. In nature, isohedral structures are found at the nano level. Usually made from many protein subunits and having a hollow interior, these protein cages carry out many important tasks. The most famous examples are viruses that use protein cages as a carrier of viral genetic material into host cells.

Synthetic biologists, for their part, are interested in making artificial protein cages in the hope of imparting them with useful and novel properties. There are two challenges to achieving this goal. The first is the geometry problem—some candidate proteins may have great potential utility, but are automatically ruled out because they have the wrong shape to assemble into cages. The second problem is complexity—most protein-protein interactions are mediated via complex networks of weak chemical bonds that are very difficult to engineer from scratch.

Continue reading “Researchers create ‘impossible’ nano-sized protein cages with the help of gold” »

In an article last May, we covered how Rejuvenate Bio, a startup biotech company led by Professor George Church, was planning to reverse aging in dogs as a step towards bringing these therapies to us. Those plans are now starting to move forward with news of a trial launch in the fall later this year.

Developing anti-aging therapies in dogs is the first step

Back in 2015, the Church lab at Harvard began testing a variety of therapies focused on age reversal using CRISPR, a gene editing system that was much easier and faster to use than older techniques. Since then, Professor Church and his lab have conducted a myriad of experiments and gathered lots of data with which to plan future strategies for tackling aging.

Continue reading “Anti-Aging Gene Therapy for Dogs Coming This Fall” »

Fourth patent for CRISPR-Cas9 expected in coming months as patent board works its way through past UC applications.

Neurodegenerative diseases like multiple sclerosis (MS) affect millions of people worldwide and occur when parts of the nervous system lose function over time. Researchers at the University of Maryland School of Medicine (UMSOM) have discovered that a type of skin-related stem cell could be used to help regenerate myelin sheaths, a vital part of the nervous system linked to neurodegenerative disorders.

The discovery into these types of stem cells is significant because they could offer a simpler and less invasive alternative to using embryonic stem cells. This early stage research showed that by using these skin-related stem cells, researchers were able to restore myelin sheath formation in mice.

“This research enhances the possibility of identifying human skin stem cells that can be isolated, expanded, and used therapeutically. In the future, we plan to continue our research in this area by determining whether these cells can enhance functional recovery from neuronal injury,” said Thomas J. Hornyak, MD, PhD, Associate Professor and Chairman of the Department of Dermatology, and Principal Investigator in this research. “In the future, we plan to continue our research in this area by determining whether these cells can enhance functional recovery from neuronal injury.”

Continue reading “Skin-derived Stem Cell has Potential to Regenerate Myelin Sheath” »

Although most of the research on the endocannabinoid system focuses on its involvement in the CNS and immune systems, a significant amount of research over the past 20 years has demonstrated that this system also plays a role in maintaining several important functions of the skin. This article will examine the functions of the endocannabinoid system on the skin and its involvement in several skin conditions.

It could let everyone benefit from good genes.

Brains contain a variety of immune cells that play an important role for brain function. A team led by Prof. Kiavash Movahedi (VIB Center for Inflammation Research at VUB) has developed a comprehensive cell atlas of the brain’s immune compartment. This revealed not only the striking diversity of brain macrophages, but also uncovered microglia where they were not expected. Remarkably, these previously unknown microglia showed a clear resemblance to microglia that are normally associated with neurodegenerative disorders such as Alzheimer’s disease. The new insights are important for understanding the role of macrophages in healthy brain physiology and for developing future treatments for neurodegenerative diseases.

Macrophages in the brain were first discovered 100 years ago by the Spanish scientist P\xEDo del R\xEDo-Hortega. Most brain macrophages are known as microglia. These cells are in close contact with neurons and are critical for the proper development and functioning of the brain. But beyond the microglia, brains house several other types of macrophages, many of which are relatively unknown.

Prof. Kiavash Movahedi (VIB Center for Inflammation Research, VUB), said, “While microglia are fairly well studied, other brain macrophages have remained quite enigmatic. We wanted to obtain a better understanding of these cells, as we believe they could be critical for regulating brain inflammation and immunity.”

Continue reading “Detailed brain map uncovers hidden immune cells that may be involved in neurodegenerative disorders” »

Intellia and its research collaborator, IRCCS Ospedale San Raffaele presented new in vitro data showing that CRISPR/Cas9 editing resulted in over 98% knockout of the endogenous T cell receptor (TCR), while achieving transfer of various Wilms’ Tumor 1 (WT1)-specific TCRs into over 95% of isolated T cells.

Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells.

SOURCES- Intellia Written By Brian Wang. Nextbigfuture.com

Continue reading “Intellia Fixed 95-98% T-Cells Inside the Body Using CRISPR Gene Therapy” »

Here, doctors extract a patient’s own T cells, a type of white blood cell that normally acts as the body’s watcher against cancer and infection. Cancer cells eventually learn to evade T cells or disarm the troops—while turning their own surrounding normal cells into cancerous ones, thus expanding their tumor legion.

CAR-T uses gene therapy to recharge those beaten-down T cells. The UPenn study, for example, relies on a neutered HIV-like virus to deliver an artificial “tracker” protein into those cells. These designer trackers expertly hunt down a protein dubbed NY-ESO-1, which dot certain cancer cells’ surface like a homing beacon.

CRISPR amplifies the CAR-T effect: the team is using the gene editing tool to erase three different “brakes” in T cells. Killing off the first two, TCR α and TCR β, keeps the edited cells in check to prevent friendly autoimmune fire, and allows the added “tracker proteins” to thrive in large numbers. Wiping out the third, PD-1, prevents a phenomenon called T cell exhaustion. It’s aptly named: here, tumor cells secrete molecules that literally shut down T cell activity, zapping away their killing power.

Continue reading “CRISPR Used in Human Trials for the First Time in the US” »